Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reed Miller

Deputy Editor

Washington, DC
Reed, deputy editor for commercial and R&D, got his first real job in journalism in 2000 with The Gray Sheet, then part of FDC Reports, based outside of Washington, DC, and has been covering medical technology ever since. His primary focus has been clinical trials and new product development, so he has covered innumerable FDA advisory panel meetings and Medicare coverage decisions. Mixed in to his many years with The Gray Sheet, Reed spent a year in Massachusetts with HCPro in that company’s pharma compliance editorial group, and three years as a reporter for theheart.org, when it was the best news source for cardiologists. In 2015, he’s became deputy editor of Clinica, continuing to track the bewildering and rapidly evolving universe of new medical technology, from IVDs to artificial hearts, from pre-clinical trials to commercialization. Reed has a BA in religion from the College of William & Mary and an MA in Philosophy of Religion from Boston University. He lives and works in his hometown of State College, Pennsylvania.
Advertisement
Set Alert for Articles By Reed Miller

Latest From Reed Miller

Stanford Launches Trial Of NeuroPace’s Responsive Neuromodulation To Stop Overeating

The DBSLOC trial will study the feasibility of using NeuroPace’s RNS responsive neuromodulation system to stimulate the nucleus accumbens in order to stop “loss-of-control” eating in people with treatment-refractory obesity, especially those who have failed to respond adequately to gastric bypass surgery.

Clinical Trials Innovation

Brain Therapies Leads Medtronic’s Growth In First Quarter Of Fiscal 2020

The medtech giant reported revenue of $7.5bn in the quarter that ended on 26 July, up 3.5% year-over-year basis, led by 12.5% growth in revenues from emerging markets. Medtronic’s fastest-growing business is its brain therapies unit, which reported 11.4% growth in the quarter.

Sales & Earnings Innovation

FDA Approves CVRx’s Barostim Neo For Heart Failure On Expedited Pathway

The PMA approval is based on the results of the BeAT HF trial, which showed that baroflex activation therapy with Barostim Neo safely improves quality-of-life scores and exercise capacity in patients with heart failure and reduced ejection fraction.

Approvals Clinical Trials

Medtronic, Capital District Physicians’ Health Plan Partner To 'Gamify' Diabetes Control

Health plan members will be invited to join Medtronic’s Inner Circle patient engagement program, which applies game design to help motivate and encourage patients with diabetes to achieve monthly health-outcome goals.

Commercial Healthcare Systems

FDA Expands TAVR Indication To Low-Risk Patients

As expected, the US FDA has expanded the approved indication for four transcatheter aortic valves – Edwards Lifescience’s Sapien 3 and Sapien 3 Ultra, and Medtronic’s CoreValve Evolut R and CoreValve Evolut PRO – to include patients at low risk for complications during surgery.

Approvals Clinical Trials

SENSE Results Support Biotronik’s DX System For Atrial Sensing Without An Atrial Lead

Results of the SENSE trial showed Biotronik’s DX system, which is available in both ICD and CRT-D devices, can detect atrial high-rate episodes as effectively as dual-chamber ICDs and better than single-chamber ICDs even though it does not have an atrial sensing lead.

Clinical Trials Research & Development
See All
Advertisement
UsernamePublicRestriction

Register